Background: Antipsychotic drugs are often used to treat behavioral and psychological symptoms (BPSD) in adults aged 65 years and older with dementia, although there is uncertainty about the effectiveness of long-term use for this indication and there are concerns that they may cause harm.

Objectives: To evaluate whether discontinuation of long-term antipsychotic drugs for BPSD is successful in adults aged 65 years and older with dementia. This article is based on a Cochrane review updated in 2018.

Design: A Cochrane systematic review and meta-analysis.

Setting And Participants: Eight databases were searched in January 2018 to identify 10 randomized controlled trials with 632 older adults.

Measures: We used standard methodological procedures according to the Cochrane Handbook for Systematic Reviews of Interventions. We assessed the number of patients completing the study. We considered sustained withdrawal of antipsychotics until the end of the study period as successful outcome.

Results: Based on assessment of 7 studies (n = 446), discontinuation may make little or no difference to whether or not participants complete the study (low-quality evidence). In 2 trials, including participants with psychosis, agitation, or aggression who had responded to antipsychotic treatment, discontinuation of antipsychotics was associated with a higher risk of leaving the study prematurely because of symptomatic relapse or a shorter time to symptomatic relapse. We found low-quality evidence from 7 trials (n = 519) that discontinuation may make little or no difference to overall BPSD, measured using various scales. There was some evidence from subgroup analyses in 2 trials that discontinuation may be associated with a worsening of BPSD in participants with more severe BPSD at baseline.

Conclusions: Our meta-analysis revealed that there is low-quality evidence that long-term antipsychotic drugs for BPSD may be successfully discontinued in most adults aged 65 and older.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jamda.2018.06.023DOI Listing

Publication Analysis

Top Keywords

adults aged
16
long-term antipsychotic
12
aged 65 years
12
65 years older
12
older dementia
12
antipsychotic drugs
12
discontinuation long-term
8
behavioral psychological
8
psychological symptoms
8
drugs bpsd
8

Similar Publications

Background: Maintenance of oral health, prevention, and health promotion stand as primary competencies for dental graduates. Consequently, it is necessary to promote such an approach in dental schools, which are traditionally focused on treatment, to improve the attitude and practice of students in the field of prevention, the final result of which is the reduction of oral and dental diseases in patients. The study aimed to design Integrated Oral Health Care Pathways (IOHCPs) for adults and children referred to Tehran University of Medical Sciences (TUMS), School of Dentistry.

View Article and Find Full Text PDF

Background: Obesity and metabolic syndrome are major public health concerns linked to cognitive decline with aging. Prior work from our lab has demonstrated that short-term high fat diet (HFD) rapidly impairs memory function via a neuroinflammatory mechanism. However, the degree to which these rapid inflammatory changes are unique to the brain is unknown.

View Article and Find Full Text PDF

Association of pan-immune-inflammatory value with metabolic dysfunction-associated steatotic liver disease: findings from NHANES 2017-2020.

BMC Gastroenterol

January 2025

Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, No. 55 Zhenhai Road, Xiamen, 361003, China.

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease worldwide. The pan-immune-inflammation value (PIV) has been proposed as a biomarker for assessing immune status and inflammation. There is currently no evidence regarding the effect of PIV on the risk of MASLD.

View Article and Find Full Text PDF

Aging remains the foremost risk factor for cardiovascular and cerebrovascular diseases, surpassing traditional factors in epidemiological significance. This review elucidates the cellular and molecular mechanisms underlying vascular aging, with an emphasis on sex differences that influence disease progression and clinical outcomes in older adults. We discuss the convergence of aging processes at the macro- and microvascular levels and their contributions to the pathogenesis of vascular diseases.

View Article and Find Full Text PDF

The Cardiometabolic Index (CMI) is a well-recognized risk factor for a range of cardiovascular diseases and diabetes mellitus. However, the population-level characteristics of CMI and its potential association with mortality risk among individuals over 40 years of age have not been investigated. This study aims to assess the association between CMI and both all-cause and cardiovascular mortality among the middle-aged and elderly population.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!